(RTTNews) – French pharmaceutical company Sanofi S.A. (SNYNF,SNY) said Tuesday that it completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager. Sanofi acquired DR-0201 from a private clinical-stage biopharmaceutical company Dren Bio, Inc.